Lipocine Inc.
LPCN
Rank in Stocks
#27639
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development... Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Share Price
$1.72
Last synced: 2026-11-09
Market Cap
$14.18M
Change (1 day)
9.55%
Change (1 year)
-40.48%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lipocine Inc. (LPCN)
Category
Healthcare
EPS for Lipocine Inc. (LPCN)
EPS as of September 2026 TTM: $-1.36
According to Lipocine Inc.'s latest financial reports, its current EPS (TTM) is $-1.36. At the end of 2025 the company had an EPS of $-1.77, a decrease compared to its 2024 EPS of 0.00.
EPS history for Lipocine Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.36 | -23.16% |
| 2025 | $-1.77 | -110,725.00% |
| 2024 | 0.00 | -100.05% |
| 2023 | $-3.14 | 46.05% |
| 2022 | $-2.15 | 1,031.58% |
| 2021 | $-0.19 | -97.06% |
| 2020 | $-6.46 | -24.36% |
| 2019 | $-8.54 | -8.66% |
| 2018 | $-9.35 | -47.44% |
| 2017 | $-17.79 | 0.74% |
| 2016 | $-17.66 | -6.01% |
| 2015 | $-18.79 | -30.74% |
| 2014 | $-27.13 | 10.96% |
| 2013 | $-24.45 | -269.20% |
| 2012 | $14.45 | -593.17% |
| 2011 | $-2.93 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,251.47% |
US
|
|
| $-7.07 | 419.85% |
US
|
|
| $-5.29 | 288.97% |
AU
|
|
| $12.88 | -1,047.07% |
BE
|
|
| $21.56 | -1,685.29% |
NL
|
Questions about Lipocine Inc.'s earnings per share (EPS)
What is Lipocine Inc.'s earnings per share (EPS)?
Lipocine Inc.'s earnings per share (EPS) over the last twelve months is $-1.36, as of Sep 2026.
What was Lipocine Inc.'s earnings per share (EPS) in 2025?
In 2025, Lipocine Inc.'s earnings per share (EPS) was $-1.77, compared with 0.00 in 2024.
How has Lipocine Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Lipocine Inc.'s earnings per share (EPS) was highest in 2024 (0.00) and lowest in 2020 ($-6.46).
How does Lipocine Inc.'s earnings per share (EPS) compare with similar companies?
Lipocine Inc.'s earnings per share (EPS) ($-1.36) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.